Transcriptional network and upstream regulatory factor analysis indicated that TGFβ1 pathway was essential to the pathogenic mechanism of long-term L-Dopa therapy caused dyskinesia in PD patients [16]. This evidence concerns the gene TGFB1 and Dyskinesia.